Anebulo Pharmaceuticals Inc Stock Price, News & Analysis

Anebulo Pharmaceuticals (Nasdaq: ANEB) has initiated dosing in its Phase 1 single ascending dose (SAD) study of intravenous selonabant for acute cannabis-induced toxicity. The study, supported by a $994,300 NIDA collaborative grant, aims to develop the first emergency antidote for cannabis toxicity.

The company is prioritizing the IV formulation specifically for pediatric patients, following successful Phase 2 trials of oral selonabant in adults. This strategic focus stems from children's heightened sensitivity to cannabis toxicity, which can lead to severe complications including CNS depression, respiratory depression, coma, and potentially death.

The FDA has indicated strong interest in collaborating with Anebulo to address this growing unmet medical need in pediatric cannabis toxicity treatment.

Anebulo Pharmaceuticals (Nasdaq: ANEB), a clinical-stage biopharmaceutical company focused on cannabinoid-induced toxicities treatments, has provided an update on its previously announced going private transaction from July 23, 2025. The company has received interest from potential financial and strategic partners, prompting the Board to review all strategic alternatives.

The strategic options under consideration include the proposed going private transaction and reverse stock split, a potential sale of company assets, and possible merger transactions. While this review is ongoing, Anebulo plans to proceed with a special stockholder meeting to vote on the proposed reverse stock split, though the Board maintains discretion to abandon the split even if approved.

Anebulo Pharmaceuticals (Nasdaq: ANEB) has announced plans to go private through a significant reverse stock split at a ratio between 1-for-2,500 and 1-for-7,500. The company will pay $3.50 per pre-split share in cash for fractional shares, representing a 91% premium over the July 22, 2025 closing price.

Stockholders holding fewer than the minimum number of shares (between 2,500 and 7,500) will be cashed out, while larger holders will receive one post-split share for every minimum number of pre-split shares. The company cites burdensome costs of being a public reporting company as the primary reason for this decision, aiming to focus on product development and cost reduction.

Anebulo Pharmaceuticals (NASDAQ: ANEB) reported its Q3 FY2025 financial results and provided updates on its clinical development program. The company is advancing intravenous selonabant as a potential treatment for pediatric patients with cannabis-induced Central Nervous System (CNS) depression. Anebulo plans to initiate a Phase 1 single ascending dose (SAD) study in healthy adult volunteers aged 18-25 years in Q3 2025.

Financial highlights include operating expenses of $1.9 million (vs $1.7M in Q3 FY2024), a net loss of $1.7 million or $(0.04) per share, and cash and cash equivalents of $13.3 million as of March 31, 2025. The company has access to an additional $3 million through a Loan Agreement.

Anebulo Pharmaceuticals (ANEB) reported Q2 FY2025 financial results and updates on their lead product candidate, selonabant, designed to treat acute cannabis-induced toxic effects. The company secured $15 million through a private placement of 15.2 million shares and amended its Loan Security Agreement to $3 million.

Key developments include FDA discussions regarding intravenous selonabant development, with the agency acknowledging the unmet need for treating cannabis toxicity in children. The company plans to begin Phase 1 single ascending dose study in 1H25.

Financial results show operating expenses of $2.6 million in Q2 FY2025, down from $2.8 million year-over-year. Net loss was $2.5 million ($0.09 per share) compared to $2.7 million ($0.11 per share) in Q2 FY2024. Cash position stands at $15.0 million as of December 31, 2024.

Anebulo Pharmaceuticals (ANEB) announced positive regulatory progress for selonabant in treating acute cannabis-induced toxicity in children and secured a $15 million capital raise. The company's Phase 2 proof-of-concept study with 134 adult subjects demonstrated that oral selonabant effectively blocked or reversed key CNS effects of THC. The FDA acknowledged the unmet need for treating children exposed to cannabis toxicity and proposed ongoing collaboration.

The company secured a private placement of 15.2 million shares at $0.99 per share, priced at-the-market under Nasdaq rules. Additionally, Anebulo will modify its Loan and Security Agreement, reducing the maximum loan size to approximately $3 million. The company plans to initiate a Phase I SAD study of IV selonabant in healthy adults in first half of 2025.

Anebulo Pharmaceuticals (ANEB) has reported its Q1 FY2025 financial results and updates. The company received the first tranche of a $1.9 million NIDA grant to advance its intravenous selonabant formulation for treating acute cannabis-induced toxicities. The company plans to complete IND-enabling activities by end of 2024 and enroll first volunteers in H1 2025. Financial results show operating expenses of $2.4 million, with a net loss of $2.2 million ($0.08 per share). Cash position stands at $1.4 million, with access to an additional $10 million through a recent Loan Agreement.

Anebulo Pharmaceuticals (Nasdaq: ANEB) reported financial results for Q4 and FY 2024, ending June 30, 2024. Key highlights include:

1. Awarded first tranche of a $1.9 million grant from NIDA/NIH
2. Prioritizing development of selonabant IV formulation for unintentional cannabis poisoning in children
3. Q4 FY2024 operating expenses: $1.3 million (vs $2.5 million in Q4 FY2023)
4. Q4 FY2024 net loss: $1.3 million or $(0.05) per share
5. FY2024 operating expenses: $8.3 million (vs $11.8 million in FY2023)
6. FY2024 net loss: $8.2 million or $(0.32) per share
7. Cash and cash equivalents: $3.1 million as of June 30, 2024
8. Access to additional $10 million through Loan and Security Agreement

Anebulo Pharmaceuticals (Nasdaq: ANEB) has been awarded a two-year cooperative grant of up to $1.9 million from the National Institute on Drug Abuse (NIDA) to support the development of intravenous selonabant. This potential emergency treatment targets acute cannabis-induced toxicities, particularly cannabis-induced CNS depression in children.

The grant is structured in two tranches: an initial $0.9 million award, followed by approximately $1 million subject to meeting certain milestones. This funding acknowledges the growing unmet medical need for a cannabis antidote, especially for children who are more susceptible to cannabis toxicity due to their underdeveloped endocannabinoid system.

Anebulo's CSO, Ken Cundy, emphasized that this grant provides validation for their work, while CEO Richie Cunningham highlighted how it aligns with their recent decision to prioritize the development of the intravenous formulation of selonabant.